Daclizumab - AbbVie/Biogen
At a glance
- Drug Originator PDL BioPharma
- Drug Licenced by Biogen; UCB
- Drug Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antineoplastics; Antipsoriatics; Antivirals; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunosuppressants; Interleukin 2 receptor antagonists
- USA Patent Applicants BIOGEN
- USA Patents 222
- BLAs 1
- International Patents 2,609

Disclaimer